You don't know for sure. However, in this case, primary endpoint is PFS rather than OS, and Nexavar data have been consistent in trials and real practice. I have been on the record saying I expect positive trial result from Tivozanib vs Nexavar, with or without this delay.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.